Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
1. An isolated anti-ROR1 antibody comprising a humanized heavy chain variable region and a humanized light chain variable region,
wherein said humanized heavy chain variable region comprises the sequences set forth in SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29; and
wherein said humanized light chain variable region comprises the sequences set forth in SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32.
2. The isolated antibody according to claim 1 , wherein the antibody binds to amino acids 130-160 of hROR-1.
3. The isolated antibody according to claim 2 , wherein the antibody requires that ROR1 amino acid 138 is glutamic acid for binding to hROR-1.
4. The isolated antibody according to claim 1 , wherein the antibody has a binding affinity of about 500 pM to about 6 nM.
5. The isolated antibody according to claim 4 , wherein the binding affinity is about 800 pM.
6. The isolated antibody according to claim 1 , wherein the antibody inhibits metastasis.
7. The isolated antibody according to claim 1 , wherein the antibody is human, humanized or chimeric.
8. The isolated antibody according to claim 1 , wherein the antibody is conjugated to a therapeutic agent.